Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for immune-mediated dermatologic and inflammatory diseases. The company’s pipeline comprises both topical and oral drug candidates designed to address significant unmet medical needs in conditions such as actinic keratosis, atopic dermatitis, and alopecia areata. Aclaris employs a precision medicine approach, leveraging its immuno-dermatology platform to advance targeted therapies through clinical development.
The company’s lead program, A-101, is a topical formulation to treat actinic keratosis, a precancerous skin condition. A-101 combines a proprietary gel formulation with synthetic hypericin, aiming to improve lesion clearance with minimal application steps. In addition to A-101, Aclaris is developing a suite of janus kinase (JAK) inhibitors, including ATI-1777 and ATI-1779, formulated for topical use in inflammatory skin disorders, as well as ATI-450, an oral small molecule inhibitor targeting inflammatory pathways for systemic autoimmune diseases.
Founded in 2015 and headquartered in Wayne, Pennsylvania, Aclaris operates research and development facilities in the United States and maintains collaborations in Europe and Asia to support global clinical trials. The company’s multidisciplinary team combines expertise in dermatology, immunology, chemistry, and clinical development to advance its product candidates through regulatory milestones and toward potential commercialization.
Aclaris is led by a management team with deep industry experience, including a seasoned executive board and scientific advisory committee. The leadership team’s collective background spans major pharmaceutical and biotechnology firms, bringing a track record of successful drug development, regulatory approvals, and strategic partnerships. With multiple ongoing clinical studies, Aclaris Therapeutics aims to become a leader in treating immune-mediated dermatologic diseases by delivering innovative therapies that improve patient outcomes.
AI Generated. May Contain Errors.